glp 1 and afib GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies New research presented at #HRS2026

Tirzepatide activates both GLP-1 and GIP receptors, often producing more pronounced appetite suppression and weight loss than semaglutide alone

While most users arent required to submit blood work, those with diabetes or pre-diabetes are encouraged to upload results for a more tailored evaluation

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and metaanalysis including the 2year STEP 5 trial

Log into your UHC member portal or the OptumRx app and search the formulary for Wegovy

If you develop severe vomiting or dehydration while taking both medications, contact your healthcare provider promptly, as they may recommend temporarily pausing semaglutide until you recover

The analysis found that early in-trial weight loss was not related to subsequent cardiovascular benefit after the first 20 weeks